Press Release

ZEISS to invest in Mindpeak to accelerate AI-based digital pathology

Funding boosts clinical labs and biopharma companies worldwide.

30 September 2024

Oberkochen, Germany | 30 September 2024 | ZEISS Group

Mindpeak, founded in 2018 specializing in the development and commercialization of AI-powered pathological solutions, today announced it has raised $15.3 million in a Series A funding round.

ZEISS Ventures co-led the round together with InnoVentureFund with participation from – amongst others – AI.Fund and the European Innovation Council Fund. The investment will enable the company to further expand the commercialization of its pioneering technologies across several geographical areas.

Mindpeak’s AI algorithms were among the first to be deployed for routine clinical diagnostics in both the US and EU. The company’s innovative solutions enable automated histological and immunohistochemical tissue analysis, helping experts make more competent decisions.

"With this new capital, we will accelerate the development and deployment of our AI solutions, empowering pathologists and researchers with faster, more accurate diagnostic tools," said Felix Faber, CEO of Mindpeak. "Our goal is to revolutionize cancer diagnostics and, ultimately, improve patient outcomes."

“We are excited about our investment Mindpeak, a leader in the advancement of digital pathology. This partnership is a natural extension of our ongoing dedication to fostering innovation within the life sciences and healthcare sectors. Together, we are committed to driving technologies that will significantly enhance patient outcomes," explains Dr. Boris Hofmann, Head of ZEISS Ventures.

ZEISS to invest in Mindpeak to accelerate AI-based digital pathology

About Mindpeak

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care. For more information, visit mindpeak.ai, Twitter, and LinkedIn.

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 44,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, 35 research and development facilities, and 35 production facilities worldwide (status: 31 March 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com